Literature DB >> 21544746

Proteome-based pathway modelling of psychiatric disorders.

C W Turck1, F Iris.   

Abstract

The etiopathogenesis of many psychiatric illnesses remains unclear and a variety of these diseases can coexist, partly mimicking each other while contributing to and distorting symptomatic expressions. To understand the processes involved, it is necessary to unravel signalling pathways, complex interaction networks and metabolic alterations involving a plethora of anatomical components. When addressing such largely obscure mechanisms, primary data mainly based on genomics and differential gene expression patterns turns out to be of limited usefulness. Numerous direct as well as very indirect processes modulate and dissociate gene expression from protein functions and physiological effects. Proteomics approaches that utilise metabolic labelling and high-throughput mass spectrometry to provide proteome dynamics data need to be utilised. However, the data thus gathered encompasses a complex assembly of numerous types of intermixed cells, representing biological processes that occur in both time and space across several scalar levels. The complexities represented are such that to analytically approach these diseases, a systems standpoint becomes necessary. This implies multiple experimental interrogations in an iterative interplay between experimentation and modelling. While this may be reasonably considered in the context of in vitro systems, it can hardly be contemplated when addressing CNS tissues from heterogeneous human origins, thereby imposing serious constraints upon the investigation of human cognitive disorders. In this article, the authors expose a paradigm that addresses and alleviates at least some of these major difficulties. Based on the reasoned utilisation of trait animal models and human material, this approach has already started to deliver novel and directly exploitable knowledge. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544746     DOI: 10.1055/s-0031-1271701

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  6 in total

Review 1.  What Have Mass Spectrometry-Based Proteomics and Metabolomics (Not) Taught Us about Psychiatric Disorders?

Authors:  Christoph W Turck; Michaela D Filiou
Journal:  Mol Neuropsychiatry       Date:  2015-05-12

Review 2.  The potential of biomarkers in psychiatry: focus on proteomics.

Authors:  Izabela Sokolowska; Armand G Ngounou Wetie; Kelly Wormwood; Johannes Thome; Costel C Darie; Alisa G Woods
Journal:  J Neural Transm (Vienna)       Date:  2013-12-20       Impact factor: 3.575

Review 3.  A new mechanistic approach for the treatment of chronic neuropathic pain with nitrous oxide integrated from a systems biology narrative review.

Authors:  Baptiste Bessiere; François Iris; Aude Milet; Athanasios Beopoulos; Catherine Billoet; Géraldine Farjot
Journal:  Med Gas Res       Date:  2021 Jan-Mar

Review 4.  Potential biomarkers in psychiatry: focus on the cholesterol system.

Authors:  Alisa G Woods; Izabela Sokolowska; Regina Taurines; Manfred Gerlach; Edward Dudley; Johannes Thome; Costel C Darie
Journal:  J Cell Mol Med       Date:  2012-06       Impact factor: 5.310

5.  Autonomic Nervous System Neuroanatomical Alterations Could Provoke and Maintain Gastrointestinal Dysbiosis in Autism Spectrum Disorder (ASD): A Novel Microbiome-Host Interaction Mechanistic Hypothesis.

Authors:  Athanasios Beopoulos; Manuel Gea; Alessio Fasano; François Iris
Journal:  Nutrients       Date:  2021-12-24       Impact factor: 5.717

Review 6.  Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder.

Authors:  Daniel Martins-de-Souza
Journal:  Dialogues Clin Neurosci       Date:  2014-03       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.